JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     




This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hemm, S.
Right arrow Articles by Coubes, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hemm, S.
Right arrow Articles by Coubes, P.
Journal of Nuclear Medicine Vol. 46 No. 7 1151-1157
© 2005 by Society of Nuclear Medicine


Clinical Investigations

Stereotactic Coregistration of 201Tl SPECT and MRI Applied to Brain Tumor Biopsies

Simone Hemm, BME1, Valérie Rigau, MD2, Jeanine Chevalier, MD3, Marie C. Picot, MD, PhD4, Luc Bauchet, MD, PhD5, Hassan El Fertit, MD5, Marie-Ange Rodriguez, MD5, Laura Cif, MD1,5, Nathalie Vayssière, PhD1, Michel Zanca, MD, PhD3, Pierre Baldet, MD, PhD2, François Segnarbieux, MD, PhD5 and Philippe Coubes, MD, PhD1,5

1 Research Unit on Movement Disorders (URMA), University Hospital, Montpellier, France; 2 Anatomopathology Department, University Hospital, Montpellier, France; 3 Biophysics and Nuclear Medicine Department, University Hospital, Montpellier, France; 4 Biostatistics Department, University Hospital, Montpellier, France; 5 Neurosurgery Department, University Hospital, Montpellier, France

The aim of the present study was to determine the clinical feasibility of integration of stereotactic SPECT (sSPECT) with 201Tl in the stereotactic MRI (sMRI)-based planning of brain tumor biopsy. Furthermore, the predictive value of the integrated techniques was analyzed by comparison with the corresponding histologically determined metabolic activity. Methods: Ten patients underwent combined 201Tl SPECT- and MRI-guided stereotactic biopsy of intracranial lesions according to a previously described technique. An area of abnormal 201Tl uptake was used to guide the stereotactic biopsy trajectory. Several samples were taken along the trajectory above and beneath the target. An extensive histologic diagnosis (tumor grade, mitotic index [MI], and Ki67 index) and the 201Tl index were obtained for all samples and compared statistically. Results: Combined 201Tl sSPECT- and sMRI-guided biopsy could be performed on all patients. Ki67 index, MI, and tumor grade correlated significantly. The correlations between MI or Ki67 index and 201Tl index were not significant (0.18 and 0.09, respectively). A trend to significance existed between tumor grade and 201Tl index (R = 0.31; P = 0.06). Mean 201Tl index for grade III tumors (3.27 ± 1.89 [SD]) was significantly different from that for grade IV tumors (4.34 ± 1.29). The sample position on the trajectory correlated with the MI (R = 0.39; P = 0.01). In 4 of the 10 patients, a variation in tumor grade could be observed along the trajectory. In all patients, the highest proliferative activity was within 5–10 mm of the target. Conclusion: These results support the view that 201Tl SPECT may contribute to the successful management of brain tumor patients requiring stereotactic biopsy, without causing a significant increase in discomfort or morbidity. The development of similar techniques integrating sSPECT data in the planning of stereotactic biopsy should be considered by centers performing stereotactic surgery and having access to SPECT technology. In the long term, this technique could become a support for focused gene therapy and cell transfer.

Key Words: stereotactic 201Tl SPECT • stereotactic MRI • coregistration • biopsy • brain tumors







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.